LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies

Executive Summary

• LIR Life Sciences filed a provisional patent application titled “Transdermal and Lingual Delivery System for GLP‑1 Inhibitors” with the USPTO to protect its needle‑free delivery platform for GLP/GIP‑based obesity and metabolic disease therapies.
• The filing covers both composition of matter and methods of administration (patches, creams, gels) and is intended to support a broad platform that can accommodate multiple existing and future GLP‑1/GIP drugs.
• The patent effort complements ongoing preclinical work, including a mouse glucose‑tolerance study announced on December 10, 2025, aimed at demonstrating biological activity of the skin‑applied formulation.

Key Details

• Provisional Patent Application: Filed with USPTO; title “Transdermal and Lingual Delivery System for GLP‑1 Inhibitors.”
• Scope of Protection: Includes specific compositions (carrier technology) and administration methods (transdermal patches, creams, gels) for delivering GLP/GIP‑based therapies through the skin.
• Strategic Goal: Build a platform covering the entire GLP/GIP drug class rather than a single product, enabling compatibility with multiple current and future therapeutics.
• Preclinical Linkage: Supports ongoing preclinical program; mouse study (announced Dec 10, 2025) will test CPP‑enabled skin formulation using glucose tolerance tests to assess biological activity.
• Long‑Term Objective: Provide needle‑free obesity treatments that improve patient adherence, reduce injection burden, and expand access in settings where injectable programs are challenging.
• CEO Quote: “Filing of this provisional patent application is a step towards securing protection for our delivery platform, which is essential as we progress the design of formulations capable of moving GLP/GIP‑based therapies through the skin and into systemic circulation.” – Edward Mills, CEO

Notable Quotes

“Filing of this provisional patent application is a step towards securing protection for our delivery platform, which is essential as we progress the design of formulations capable of moving GLP/GIP‑based therapies through the skin and into systemic circulation,” — Edward Mills, Chief Executive Officer.